Anjarium Biosciences AG announced that it has received CHF 55.5 million in a round of funding co-led by new investors Abingworth LLP and GIMV NV on September 16, 2021. The transaction also included participation from Omega Fund Management, LLC, Pfizer Venture Investments LLC and Citadel Multi-Strategy Equities Master Fund Ltd., a fund managed by Citadel Advisors LLC. Bali Muralidhar from Abingworth LLP, Bram Vanparys from GIMV NV and Dina Chaya from Omega Fund Management, LLC will join the company's board of directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.6 EUR | +1.25% | -0.45% | +0.68% |
Apr. 15 | European Commission OKs Gimv Takeover by WorxInvest | MT |
Apr. 15 | Gimv: EU approves acquisition by WorxInvest | CF |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.68% | 1.32B | |
-6.44% | 89.1B | |
+15.32% | 83.96B | |
+12.36% | 26.03B | |
-6.65% | 17.21B | |
+6.74% | 13.87B | |
-16.11% | 13.21B | |
+16.00% | 9.45B | |
+26.11% | 8.65B | |
+27.22% | 6.92B |
- Stock Market
- Equities
- GIMB Stock
- News Gimv NV
- Anjarium Biosciences AG announced that it has received CHF 55.5 million in funding from Abingworth LLP, GIMV NV, Omega Fund Management, LLC, Pfizer Venture Investments LLC, Citadel Advisors LLC